Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca Pulls Twitter Ads, Showing Risks Of Expansive Social Media Platforms

This article was originally published in The Pink Sheet Daily

Executive Summary

Company thought sponsored messages on AP’s feed were unbranded, but realized drug name showed up in expanded tweet. Did intricacies of the platform produce an inadvertent violation?


Related Content

Social Media Marketing: FDA’s Old-Time Approach May Turn Industry Away
Social Media For Pharma: Focus On Building Community, Not Brands
Keywords Not Major Advertising Enforcement Concern, FDA Says
FDA’s Biggest DTC Advertising Study Eyes Online Promotion
Rx Firms Still Bear Promotional Compliance Burden If Social Media Platform Changes, FDA Says
DDMAC Dislike: FDA Cracks Down On Facebook Widget Used On Tasigna Website
Internet Promotions Must Be Redesigned After FDA Cites Sponsored Web Links


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts